THMO

Thermogenesis Holdings Inc

THMO, USA

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

https://www.thermogenesis.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
THMO
stock
THMO

ThermoGenesis Holdings (THMO): Micro?cap volatility, quiet newsflow, and an unforgiving year for spe AD HOC NEWS

Read more →
THMO
stock
THMO

Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory Yahoo Finance

Read more →

Showing 2 of 7

Analyst Ratings & Sentiment

(Last Updated 2024-03-31)

Rating:

BUY

Target Price:

$5

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-03-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-190.36 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-18.40 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-19.18 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

11.46

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Thermogenesis Holdings Inc

1.

NT US Market Cap Idx Fd - L

(0.0001%)

since

2023/12/31

2.

Parallel Advisors, LLC

(0%)

since

2024/06/30

3.

Wells Fargo & Co

(0%)

since

2024/06/30

4.

Tower Research Capital LLC

(0%)

since

2024/06/30

5.

FMR Inc

(0%)

since

2024/06/30

6.

UBS Group AG

(0%)

since

2024/06/30

7.

Atlantic Trust Group, LLC

(0%)

since

2024/06/30

9.

Qube Research & Technologies

(0%)

since

2024/06/30

10.

Vanguard Group Inc

(0%)

since

2024/06/30

11.

Geode Capital Management, LLC

(0%)

since

2024/06/30

12.

Raymond James & Associates

(0%)

since

2024/06/30

13.

Virtu Financial LLC

(0%)

since

2024/06/30

14.

BlackRock Inc

(0%)

since

2024/06/30

15.

Advisor Group Holdings, Inc.

(0%)

since

2024/09/30

16.

Bank of America Corp

(0%)

since

2024/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-03-31

EPS Actual

-0.46

EPS Estimate

0.01

EPS Difference

-0.47

Surprise Percent

-4700%

Investing Fit Scorecard

(Last Updated 2024-03-31)

Deep Value
Potential Value Candidate(5.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2024-03-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-03-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-03-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.